,address1,address2,city,state,zip,country,phone,fax,website,industry,sector,longBusinessSummary,fullTimeEmployees,companyOfficers,auditRisk,boardRisk,compensationRisk,shareHolderRightsRisk,overallRisk,governanceEpochDate,compensationAsOfEpochDate,maxAge,priceHint,previousClose,open,dayLow,dayHigh,regularMarketPreviousClose,regularMarketOpen,regularMarketDayLow,regularMarketDayHigh,payoutRatio,beta,forwardPE,volume,regularMarketVolume,averageVolume,averageVolume10days,averageDailyVolume10Day,bid,ask,bidSize,askSize,marketCap,fiftyTwoWeekLow,fiftyTwoWeekHigh,priceToSalesTrailing12Months,fiftyDayAverage,twoHundredDayAverage,trailingAnnualDividendRate,trailingAnnualDividendYield,currency,enterpriseValue,profitMargins,floatShares,sharesOutstanding,heldPercentInsiders,heldPercentInstitutions,bookValue,priceToBook,lastFiscalYearEnd,nextFiscalYearEnd,mostRecentQuarter,netIncomeToCommon,trailingEps,forwardEps,enterpriseToRevenue,enterpriseToEbitda,exchange,quoteType,symbol,underlyingSymbol,shortName,longName,firstTradeDateEpochUtc,timeZoneFullName,timeZoneShortName,gmtOffSetMilliseconds,currentPrice,targetHighPrice,targetLowPrice,targetMeanPrice,targetMedianPrice,recommendationMean,recommendationKey,numberOfAnalystOpinions,totalCash,totalCashPerShare,ebitda,totalDebt,quickRatio,currentRatio,totalRevenue,debtToEquity,revenuePerShare,returnOnAssets,returnOnEquity,grossProfits,freeCashflow,operatingCashflow,revenueGrowth,grossMargins,ebitdaMargins,operatingMargins,financialCurrency,trailingPegRatio
0,3020 Carrington Mill Blvd.,Suite 475,Morrisville,NC,27560,United States,212 554 4484,212 554 4531,https://www.tgtherapeutics.com,Biotechnology,Healthcare,"TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell diseases. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; Novimmune SA; and Jubilant Biosys, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.",244,"{'maxAge': 1, 'name': 'Mr. Michael S. Weiss Esq.', 'age': 56, 'title': 'Chairman, CEO & Pres', 'yearBorn': 1966, 'fiscalYear': 2022, 'totalPay': 1968750, 'exercisedValue': 0, 'unexercisedValue': 2465000}",4,10,10,5,10,1693526400,1672444800,86400,2,9.364,9.472,9.472,9.472,9.364,9.472,9.472,9.472,0.0,2.089211,-4.136245,670,670,277,227,227,9.454,9.576,150000,150000,1439781888,5.036,32.71,59.861214,13.00856,16.02881,0.0,0.0,EUR,1301116032,0.0,123032033,150978000,0.085889995,0.64761,0.287,33.003483,1672444800,1703980800,1688083200,-175652992,-1.2,-2.29,54.096,-7.724,FRA,EQUITY,NKB2.F,NKB2.F,"TG THERAPEUTICS  DL -,001","TG Therapeutics, Inc.",1382508000,Europe/Berlin,CEST,7200000,9.472,84.0,33.0,59.88,58.0,1.9,buy,8,144904992,1.027,-168442000,109017000,2.235,2.87,24052000,269.49,0.174,-0.44625,-2.0727499,2520000,-99841000,-160272000,26.061,0.88471,0.0,-7.0136,USD,
1,3020 Carrington Mill Blvd.,Suite 475,Morrisville,NC,27560,United States,212 554 4484,212 554 4531,https://www.tgtherapeutics.com,Biotechnology,Healthcare,"TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell diseases. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; Novimmune SA; and Jubilant Biosys, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.",244,"{'maxAge': 1, 'name': 'Mr. Sean A. Power CPA, CPA', 'age': 40, 'title': 'CFO, Corp. Sec. & Treasurer', 'yearBorn': 1982, 'fiscalYear': 2022, 'totalPay': 652600, 'exercisedValue': 0, 'unexercisedValue': 1398200}",4,10,10,5,10,1693526400,1672444800,86400,2,9.364,9.472,9.472,9.472,9.364,9.472,9.472,9.472,0.0,2.089211,-4.136245,670,670,277,227,227,9.454,9.576,150000,150000,1439781888,5.036,32.71,59.861214,13.00856,16.02881,0.0,0.0,EUR,1301116032,0.0,123032033,150978000,0.085889995,0.64761,0.287,33.003483,1672444800,1703980800,1688083200,-175652992,-1.2,-2.29,54.096,-7.724,FRA,EQUITY,NKB2.F,NKB2.F,"TG THERAPEUTICS  DL -,001","TG Therapeutics, Inc.",1382508000,Europe/Berlin,CEST,7200000,9.472,84.0,33.0,59.88,58.0,1.9,buy,8,144904992,1.027,-168442000,109017000,2.235,2.87,24052000,269.49,0.174,-0.44625,-2.0727499,2520000,-99841000,-160272000,26.061,0.88471,0.0,-7.0136,USD,
2,3020 Carrington Mill Blvd.,Suite 475,Morrisville,NC,27560,United States,212 554 4484,212 554 4531,https://www.tgtherapeutics.com,Biotechnology,Healthcare,"TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell diseases. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; Novimmune SA; and Jubilant Biosys, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.",244,"{'maxAge': 1, 'name': 'Jenna  Bosco', 'title': 'Sr. VP of Corp. Communications', 'exercisedValue': 0, 'unexercisedValue': 0}",4,10,10,5,10,1693526400,1672444800,86400,2,9.364,9.472,9.472,9.472,9.364,9.472,9.472,9.472,0.0,2.089211,-4.136245,670,670,277,227,227,9.454,9.576,150000,150000,1439781888,5.036,32.71,59.861214,13.00856,16.02881,0.0,0.0,EUR,1301116032,0.0,123032033,150978000,0.085889995,0.64761,0.287,33.003483,1672444800,1703980800,1688083200,-175652992,-1.2,-2.29,54.096,-7.724,FRA,EQUITY,NKB2.F,NKB2.F,"TG THERAPEUTICS  DL -,001","TG Therapeutics, Inc.",1382508000,Europe/Berlin,CEST,7200000,9.472,84.0,33.0,59.88,58.0,1.9,buy,8,144904992,1.027,-168442000,109017000,2.235,2.87,24052000,269.49,0.174,-0.44625,-2.0727499,2520000,-99841000,-160272000,26.061,0.88471,0.0,-7.0136,USD,
3,3020 Carrington Mill Blvd.,Suite 475,Morrisville,NC,27560,United States,212 554 4484,212 554 4531,https://www.tgtherapeutics.com,Biotechnology,Healthcare,"TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell diseases. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; Novimmune SA; and Jubilant Biosys, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.",244,"{'maxAge': 1, 'name': 'Mr. Adam  Waldman', 'title': 'Chief Commercialization Officer', 'exercisedValue': 0, 'unexercisedValue': 0}",4,10,10,5,10,1693526400,1672444800,86400,2,9.364,9.472,9.472,9.472,9.364,9.472,9.472,9.472,0.0,2.089211,-4.136245,670,670,277,227,227,9.454,9.576,150000,150000,1439781888,5.036,32.71,59.861214,13.00856,16.02881,0.0,0.0,EUR,1301116032,0.0,123032033,150978000,0.085889995,0.64761,0.287,33.003483,1672444800,1703980800,1688083200,-175652992,-1.2,-2.29,54.096,-7.724,FRA,EQUITY,NKB2.F,NKB2.F,"TG THERAPEUTICS  DL -,001","TG Therapeutics, Inc.",1382508000,Europe/Berlin,CEST,7200000,9.472,84.0,33.0,59.88,58.0,1.9,buy,8,144904992,1.027,-168442000,109017000,2.235,2.87,24052000,269.49,0.174,-0.44625,-2.0727499,2520000,-99841000,-160272000,26.061,0.88471,0.0,-7.0136,USD,
